| Drug Name: | Anastrozole |
|---|---|
| Tablet Strength: | Commonly 1 mg film-coated oral tablets. |
| Available Packages: | Pack sizes vary by manufacturer (most commonly 28-tablet packs in the UK, though 20, 30, 84, 98, or 100 tablets also exist). |
| Price: | Generic Arimidex (anastrozole) often costs from about £3–£18 per pack of ~28–30 tablets on a private prescription, with some UK online pharmacies bringing costs into roughly £0.10–£0.60 per pill depending on supplier and quantity. |
| Rx | Prescription only. |
| Where to buy | Online Pharmacy |
Anastrozole (commonly known by the brand name Arimidex) is a potent, prescription-only aromatase inhibitor primarily used to treat hormone-receptor-positive breast cancer in postmenopausal women by significantly lowering estrogen levels in the body. Because altering hormone production requires careful clinical monitoring and baseline lab work, obtaining Anastrozole online legally and safely requires a thorough evaluation and a valid prescription from a licensed healthcare provider. While telehealth services have made it easier to consult with qualified physicians from home, purchasing Anastrozole from unverified websites without a prescription carries substantial health and legal risks. Illicit online sellers often distribute counterfeit, contaminated, or improperly dosed pills, and using this medication without medical supervision leaves you vulnerable to serious side effects—including accelerated bone mineral density loss, severe joint pain, elevated cholesterol, and increased cardiovascular risk.
An oncology clinician may prescribe anastrozole after a video or phone visit when your records establish the reason for treatment and the team can arrange follow-up. Its approved uses include certain breast cancers in postmenopausal women. An endocrinologist or reproductive urologist may assess a man for a specific off-label use. A consultation can also lead to more testing or a different treatment.
How anastrozole lowers estrogen
Aromatase and the source of estrogen
Aromatase is an enzyme that converts some androgens into estrogens. After menopause, conversion in tissues outside the ovaries accounts for much of the body's estrogen production. Anastrozole is a third-generation, nonsteroidal aromatase inhibitor. It blocks this enzyme, lowering the amount of estrogen available to stimulate estrogen receptor-positive breast cancer. The goal after surgery is to lower the chance of recurrence. With advanced disease, the goal is to control the cancer and review how it responds.
Why ovarian function matters
Functioning ovaries can respond to a drop in estrogen by increasing their activity. An aromatase inhibitor on its own generally cannot provide the estrogen suppression needed for breast cancer treatment in that setting. Some patients before menopause receive an aromatase inhibitor with prescribed ovarian suppression. That approach depends on keeping the suppression in place. Missed injections, a return of periods, or an uncertain menopause history can prompt an oncology review. The team can explain which findings would change the plan.
How tamoxifen acts differently
Tamoxifen modulates the estrogen receptor. In breast tissue, it blocks much of the effect of estrogen at that receptor. Anastrozole reduces estrogen production before the hormone reaches the receptor. The difference has practical consequences. Tamoxifen can be an option while the ovaries still function, while anastrozole generally needs ovarian suppression in that setting. Bone health, previous blood clots, and other conditions can also affect how the team compares these medicines.
Who may be offered anastrozole
Early breast cancer after surgery
Anastrozole has an approved adjuvant use for postmenopausal women with hormone receptor-positive early breast cancer. Adjuvant therapy follows treatment of the primary cancer and aims to reduce recurrence. The oncologist reads the estrogen and progesterone receptor results alongside tumor size, grade, and lymph node involvement. Any chemotherapy, radiotherapy, or previous endocrine treatment also matters. A small tumor and a larger tumor may both respond to endocrine treatment, but the amount of benefit each patient can expect can differ.
First-line treatment for advanced breast cancer
The prescribing information includes initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. If receptor status is unknown, the team may try to obtain it when feasible because it can guide the choice. The oncologist also considers recent scans, prior treatment, and whether the cancer is causing symptoms that need a faster response. Some patients receive an aromatase inhibitor with another cancer medicine. The combination can affect the schedule of visits and blood tests.
Advanced disease after progression on tamoxifen
The label also covers advanced breast cancer in postmenopausal women after progression following tamoxifen. It reports that patients with estrogen receptor-negative disease and those who had not responded to previous tamoxifen rarely responded to anastrozole in the relevant studies. That limitation matters when discussing why another endocrine treatment would help. Bring the records showing when tamoxifen started, what the scans or symptoms showed over time, and which finding prompted the proposed switch.
Treatment before menopause with ovarian suppression
A clinician may discuss ovarian suppression plus an aromatase inhibitor for selected patients whose ovaries still function. Recurrence risk, side effects, and the ability to continue suppression can influence that decision. Periods may stop for a time after chemotherapy and return. The absence of bleeding after a hysterectomy also cannot confirm menopause if the ovaries remain. Tell the team about ovarian surgery, the latest injection if you receive suppression, and any changes in bleeding. The prescriber can decide whether additional assessment would help.
When another approach may fit better
A person with established heart disease, a history of fragility fractures, or disabling joint symptoms may need a closer comparison of endocrine options. These conditions can change the monitoring plan or the choice of medicine. They do not settle the decision on their own. Ask the oncologist to explain the expected benefit of anastrozole in your situation and how they would manage the risk that matters most to you.
| Situation | What informs the decision | Treatment goal |
|---|---|---|
| Hormone receptor-positive early breast cancer after menopause | Pathology, surgery, recurrence risk, and prior treatment | Reduce the chance of recurrence |
| Locally advanced or metastatic disease | Receptor results when available, disease sites, earlier treatment, and symptoms | Control the cancer and assess response |
| Advanced disease that progressed on tamoxifen | Receptor status and whether tamoxifen helped before progression | Choose a treatment suited to the current disease |
| Functioning ovaries and a proposed aromatase inhibitor | Menopause history, recurrence risk, and ovarian suppression plan | Use endocrine therapy that matches ovarian function |
| A hormone or fertility concern in a man | Symptoms, repeated laboratory results when appropriate, and a reproductive assessment | Identify the diagnosis before considering an off-label medicine |
When a video or phone visit can work
An online visit is most useful when the clinician can see the records that determine the prescription. If an oncology team already has your pathology and treatment plan, it may be able to discuss the first prescription, manage a refill, or review side effects by video. The clinician must be able to prescribe where you are and arrange any follow-up the decision requires. If you transfer to a new clinic, ask whether it can review the original reports before the appointment.
An appointment for a new breast lump, unexplained bleeding, or pain that needs examination can require an in-person visit and further investigation. A remote appointment for a hormone concern in a man may establish what tests are needed, but a breast change or a testicular symptom can require a physical examination. Ask which part of the assessment the clinic can complete remotely. Paying for a consultation does not mean the clinician will issue a prescription.
How to request an anastrozole prescription online
1. Book with the team that can assess your condition
For breast cancer, contact the oncology team responsible for your treatment or arrange a referral. If a general clinician currently renews your prescription, use the contact in the shared care plan. For a hormone or infertility concern in a man, contact an endocrinologist or reproductive urologist. Explain the symptom or fertility concern you want assessed when booking so the clinic can arrange the right consultation.
2. Explain whether this is a first prescription, renewal, or switch
Tell the clinician whether you have taken anastrozole before and when. If you are switching from a different endocrine drug, give its name and the reason for stopping. A new diagnosis may require a pathology review. For a refill, the prescriber may only need a recent treatment letter and an update on symptoms or monitoring. An earlier prescription can establish what you took without answering whether it remains suitable.
3. Send the records that affect the prescription
Ask for copies of the pathology report, receptor results, and summary of any surgery or previous treatment. For advanced disease, include recent imaging reports and the dates of earlier drugs if the new team requests them. If you are receiving ovarian suppression, note the date of the last injection. A man seeking assessment can bring previous hormone or semen results and any records of testosterone or other hormone use.
4. Make a list of prescriptions and supplements
Include all medicines you take regularly or intermittently, including tamoxifen, estrogen-containing products, and treatments for your bones. Give the doses if you know them. For a male hormone assessment, mention testosterone injections, gels, supplements, and recent changes. The timing of a blood sample relative to a dose can affect the interpretation. A photograph of the label can be useful when you are unsure of the name.
5. Report the risks that matter before starting
Tell the team about osteoporosis, previous fractures, heart disease, high cholesterol, or an allergy to anastrozole. Report severe liver disease if it applies to you. If you could be pregnant, mention that before the appointment and ask about testing. Symptoms such as chest pain with activity or persistent bone pain are worth describing in their own right. The prescriber may need to evaluate them before choosing an endocrine regimen.
6. Arrange local testing if the clinician needs it
A remote clinician may need a bone density scan, laboratory result, or in-person examination before prescribing. Ask where you can get the test, how it will reach the clinic, and who will review it. If you already had a bone scan, give its date and send the report rather than repeating it without checking. A previous result can be useful for comparing later changes.
7. Confirm the pharmacy and the treatment directions
Give the prescriber the dispensing pharmacy's details, especially if you have recently changed it. Check the strength and directions before taking a new supply. If you are switching treatments, ask for clear stop and start dates so you do not overlap medicines by accident. Confirm the schedule of any ovarian suppression injection that forms part of your plan.
8. Know who will handle the next decision
Ask for a follow-up date and contact for prescription renewals and side effects. If another clinician will make later decisions, confirm how they receive the oncology plan. For an off-label evaluation, ask how the specialist will judge whether the treatment is helping and what would make them reconsider it. A first prescription should come with a way to ask about an unexpected result or symptom.
What the clinician checks during the consultation
Whether the diagnosis and treatment goal are clear
A prescriber distinguishes between treating an established cancer and lowering the chance that cancer will return after surgery. The initial assessment may cover when the diagnosis was made, what the pathology shows, and whether there has been a recent change in symptoms. An early cancer plan can specify a treatment course measured in years. In advanced disease, the team often reassesses the regimen as it reviews response and tolerability.
Whether menopause status changes the choice
A clinician asks about menstrual history, ovarian surgery, previous chemotherapy, and medicines that can suppress ovarian function. This context can tell them more than a single lab result. If the history leaves doubt, they may request tests or specialist review. Ask how the team would handle a return of periods or symptoms that suggest ovarian activity. This can matter even if the first few months of treatment went smoothly.
Which results are missing and why they matter
Some findings affect immediate safety. Others help the team plan longer-term follow-up. A recent fracture or possible pregnancy can change the next step, whereas a cholesterol result may guide ongoing care. Ask what question each requested test is meant to answer. Someone starting cancer treatment and someone who has already tolerated the medicine for years may need different checks.
Approved uses and off-label assessment in men
The approved cancer indications
The Arimidex prescribing information describes adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of specified advanced disease, and treatment after progression following tamoxifen in postmenopausal women. A specialist may also consider an aromatase inhibitor in a regimen outside the specific label, such as selected situations involving ovarian suppression. A prescription for a male hormone or fertility problem is off-label. Ask what evidence supports the proposed use for your diagnosis and how the clinician will follow the result.
Low testosterone and an isolated estradiol result
A clinician generally diagnoses hypogonadism when symptoms fit and appropriately measured testosterone is consistently low. They may repeat a morning sample and consider other tests to identify the cause. Estradiol results depend in part on the measurement method, especially at the lower concentrations often seen in men. A result outside a reference interval or a change in the testosterone-to-estradiol ratio cannot establish a diagnosis by itself. The clinician considers symptoms, medications, and the timing and method of the tests before deciding what to do.
Male infertility and limits of the evidence
The AUA and ASRM guideline allows specialists to consider aromatase inhibitors in selected infertile men with low testosterone. This is a conditional recommendation with limited evidence. Anastrozole can raise testosterone and lower estradiol in some men, but those laboratory changes cannot establish better sexual function or a higher chance of pregnancy. Semen findings can vary between samples. A specialist evaluates both the patient and the couple's reproductive circumstances and can explain which outcome matters for their plan.
Breast enlargement, testosterone therapy, and bodybuilding
New breast enlargement deserves an assessment of medications, hormone-related causes, and what the clinician feels on examination. A hard lump, nipple discharge, or other suspicious change can require further investigation. Guidelines do not support routine use of aromatase inhibitors for gynecomastia. Anastrozole is also not a routine accompaniment to testosterone therapy or an approved treatment for bodybuilding or post-cycle therapy. Excessively lowering estrogen can harm bone health and may affect sexual function. Bring the names and timing of any products you took so the clinician can interpret your results.
Pregnancy, contraception, and breastfeeding
When pregnancy is possible during oncology treatment
Anastrozole can harm a developing fetus. The prescribing information advises checking pregnancy status before treatment when pregnancy is possible and using effective contraception during treatment and for at least three weeks after the last dose. Discuss the method with the oncology team. Ovarian suppression is part of the cancer plan and does not replace contraception advice. Report a positive test or suspected pregnancy promptly so the team can give instructions about the prescription and next assessment.
Planning a pregnancy or breastfeeding
Tell the oncology team if you hope to become pregnant or are breastfeeding. Discuss the expected duration of endocrine therapy before making a plan with an oncology or fertility specialist. The advice on how long to use contraception after the last dose does not determine whether an interruption in cancer treatment is appropriate. The prescribing information also advises against breastfeeding during treatment and for at least two weeks after the final dose. Ask your team how those recommendations apply to your treatment plan.
Tests and follow-up during treatment
Bone density and fracture risk
Lowering estrogen with an aromatase inhibitor can reduce bone mineral density. A previous fracture after a minor injury, known osteoporosis, or other risk factors can make a baseline assessment particularly useful. A DXA scan measures bone density, typically at the hip and spine. The team can use the results and your history to plan follow-up and decide whether you need measures to prevent fractures. Weight-bearing and resistance exercise may be part of the discussion, as can adequate calcium and vitamin D intake or bone-protective treatment when indicated.
Cholesterol, heart history, and individualized testing
Anastrozole can increase total cholesterol. A clinician may order a lipid panel and consider it alongside blood pressure, diabetes, smoking, and any history of heart disease. Tell the team if you have previously had angina, a heart attack, or a procedure to open a coronary artery. Routine estradiol tests are not required for every postmenopausal patient. Testing can help in selected circumstances if the team needs to check ovarian function or assess a concern about suppression.
| Check | When it may help | What it informs |
|---|---|---|
| Pathology and receptor testing | Before starting or changing cancer therapy | Whether endocrine treatment fits the diagnosis |
| Fracture history and a bone density scan | At assessment for long-term therapy and when follow-up is due | Fracture prevention and any change in bone density |
| Lipid panel and cardiovascular history | When indicated by risk factors or the planned follow-up | Management of cholesterol and cardiovascular risk |
| Pregnancy assessment | Before starting treatment if pregnancy is possible | Whether treatment can start safely |
| Hormone or semen tests for male off-label assessment | When a specialist considers them useful for the specific diagnosis | Whether there is a treatable condition and how to follow it |
Know who will review each result and when it could affect your prescription. A clinic may order a test because of a second medicine in your cancer regimen or a condition you already have. The fact that two patients take anastrozole does not mean they need identical monitoring.
What to do when a repeat prescription is due
Your oncology plan should say whether the cancer team or another prescriber will handle refills. A remote review can be enough for an established prescription when your clinician has the information they need. Anastrozole has no special monthly registration or authorization program. Your prescriber can still set a review interval according to the treatment plan, symptoms, and other medicines you take.
When requesting a refill, give the pharmacy name, the strength on the current label, and the date your tablets will run out. Mention any missed doses, new prescriptions, or changes to ovarian suppression. If an oncology review is overdue, ask whether the team needs an appointment or test result before renewing the prescription. If your care has moved, a copy of the most recent treatment plan can help the new clinician confirm responsibility for the next supply.
How the prescriber sets the dose
The daily dose for approved breast cancer treatment
The recommended dose for the approved breast cancer indications is 1 mg by mouth once daily. The prescribing information allows it with or without food. Check the pharmacy label and ask the prescriber about any instructions that differ from your most recent treatment letter. A different strength, an unclear start date, or an apparent overlap with tamoxifen is worth resolving before using the new supply. If you have a significant liver condition, mention it when the clinician reviews the prescription.
Why oncology directions cannot guide off-label use in men
A male hormone concern calls for a different assessment, with its own goals and follow-up. A clinician who considers an aromatase inhibitor may want to review symptoms, fertility goals, and several laboratory results. A change in a blood value alone may have little value to the patient. The oncology dose does not establish a safe or effective schedule for hypogonadism, infertility, or gynecomastia. Ask the specialist how they would judge benefit and which adverse effects would lead them to reconsider the plan.
Comparing endocrine treatment options
Anastrozole and letrozole
Both are nonsteroidal aromatase inhibitors. Oncology guidance includes both as options in appropriate adjuvant settings. They can share side effects such as joint pain and loss of bone density. A patient who struggles with one may discuss trying the other with their oncology team. The clinician will consider whether the reason for switching is tolerability or concern that the cancer has progressed. A switch for side effects after surgery and a change prompted by a new site of metastatic disease call for different decisions.
Anastrozole and exemestane
Exemestane is a steroidal aromatase inhibitor that inactivates aromatase through a different mechanism. It is another option in certain treatment plans. The decision depends on the setting, previous therapy, and which other drugs the team is considering. The expected side effects also overlap. Tell the clinician when a symptom began and whether it improved during an interruption they recommended. That information can help the team judge whether trying another medicine could make treatment easier to continue.
Anastrozole and tamoxifen
Tamoxifen acts at the estrogen receptor, while anastrozole lowers estrogen production. The ATAC trial compared adjuvant treatment in postmenopausal women with early breast cancer. In the 10-year analysis, Cuzick and colleagues (2010) reported lower recurrence with anastrozole among women with hormone receptor-positive disease. The analysis found no clear difference in overall mortality between the two treatments. The recurrence result and the mortality result answer separate questions. Bone, cardiovascular, and clotting risks still matter when an individual patient chooses a treatment.
How long treatment can continue
An initial course of adjuvant endocrine therapy often lasts five years. The time already spent taking tamoxifen or another endocrine drug can count toward the total. An oncologist may discuss longer treatment with someone at higher risk of a late recurrence, particularly when lymph nodes were involved. The discussion includes what the team expects another period of treatment to add, as well as the effect on bone health, symptoms, and quality of life.
Some patients start with tamoxifen and switch to an aromatase inhibitor. In the combined ABCSG-8 and ARNO 95 analysis, Jakesz and colleagues (2005) compared switching to anastrozole after two years of tamoxifen with continuing tamoxifen. The participants were postmenopausal and had endocrine-responsive early breast cancer. Switching improved event-free survival in that analysis. This evidence informs a decision made during an existing course of therapy. The ATAC comparison instead helps answer which treatment to use initially after surgery.
For advanced breast cancer, duration depends on how the cancer responds, how the patient tolerates the regimen, and whether another treatment becomes preferable. A planned review can include symptoms or imaging. Ask who will contact you if a scan changes the plan and how to manage the medicine while waiting for that discussion.
Side effects and when to get help
Joint symptoms, hot flashes, and changes in daily life
Joint pain and stiffness are common reasons patients raise concerns about aromatase inhibitors. Report where the pain occurs, how long it lasts, and which activities it affects. Mention hot flashes, sleep disruption, fatigue, or changes in mood if they interfere with daily life. The clinician can look for other causes and discuss ways to manage symptoms or change treatment. If pain or poor sleep is making it hard to take the medicine each day, explain that at the visit.
Bone, cardiovascular, and allergic risks
Bone loss often causes no symptoms until an injury occurs. Previous fractures, osteoporosis, and concurrent ovarian suppression deserve attention when the clinician assesses risk. The prescribing information also highlights more ischemic cardiovascular events with anastrozole than with tamoxifen in the ATAC subgroup with pre-existing ischemic heart disease. That finding is particularly relevant if you have coronary artery disease. An oncologist can consider the expected breast cancer benefit alongside your cardiac history. A previous serious hypersensitivity reaction also matters before another prescription.
| Symptom or situation | What to do | What the team may assess |
|---|---|---|
| Chest pain, sudden shortness of breath, facial droop, or trouble speaking | Call emergency services immediately. | A heart attack, stroke, or another urgent cause |
| New significant pain after a fall or minor injury | Seek prompt assessment. | Possible fracture and whether the bone health plan needs review |
| Swelling of the lips or tongue, or difficulty breathing | Call emergency services immediately. | A possible serious allergic reaction |
| Joint pain, low mood, or poor sleep that interferes with daily life | Contact the prescribing team. | Other causes, symptom management, and whether to consider a treatment change |
| A positive pregnancy test while taking the medicine | Contact the prescribing team promptly. | Pregnancy status and what to do with the current prescription |
How the team assesses whether treatment is helping
When treatment follows surgery, you usually cannot feel a reduction in the risk of recurrence. Keep the follow-up visits and any breast imaging the team recommends. If you have advanced cancer, the oncologist may use symptoms, examination, imaging, and other findings to judge the response. Ask what change would lead to a different regimen. New persistent symptoms can need attention before the next scheduled visit.
For an off-label male indication, agree on a meaningful outcome before starting. A hormone result can show an effect on estrogen or testosterone, but improvement in fertility or symptoms requires a separate assessment. In a study of older men with low or borderline testosterone, Burnett-Bowie and colleagues (2009) observed higher testosterone during anastrozole treatment alongside a decline in spine bone density. That finding helps explain why a higher testosterone result alone cannot establish that treatment is beneficial.
Medicines and supplements to bring up
Tamoxifen and estrogen-containing products
Anastrozole and tamoxifen should not be taken together for the labeled breast cancer uses. Concomitant tamoxifen reduces anastrozole levels, and the adjuvant combination in ATAC did not show an efficacy benefit over tamoxifen alone. If you are switching, get written instructions for the date to stop one and start the other. Estrogen-containing products can counter the effect of anastrozole. Discuss hormone therapy, contraceptives, and any vaginal estrogen product with your oncology team before starting or changing them.
Other prescriptions, supplements, and hormone products
Show the prescriber what you take for bone health, cholesterol, sleep, or other conditions. Bring the label if a supplement lists several ingredients or you are unsure of the strength. If another clinician plans to prescribe treatment for menopausal symptoms, they need to know about your history and current endocrine regimen. In a male hormone assessment, tell the specialist if you have recently used testosterone or other hormone products because those medicines can change both symptoms and lab results.
Where to fill the prescription
Use a licensed pharmacy that requires a valid prescription. Tell the clinician whether you will collect the medicine or receive it by delivery. The service that booked your consultation may use a separate dispensing pharmacy. Ask which pharmacy holds the prescription and how you can speak to a pharmacist about the tablets or directions.
Check the patient name, medicine, strength, and directions on each supply. A generic tablet may look different when the pharmacy changes manufacturer. If a label differs from your oncology plan, ask the pharmacist or prescriber to confirm the directions. If the pharmacy cannot obtain the tablets in time, contact the clinic before you run out so it can discuss another place to dispense the same prescription.
What a consultation and prescription can cost
The consultation fee, tests, and medicine may appear as separate charges. Ask whether the first fee includes follow-up and whether the service charges for renewing an existing prescription. A pharmacy can provide a quote for the strength and quantity the clinician actually prescribes. Compare equivalent supplies. A price for one box may appear lower simply because it contains fewer tablets.
If you have coverage, ask which pharmacies you can use and what you will pay for the generic medicine and any monitoring. If you pay for care yourself, find out what a consultation, an indicated bone density scan, or a specialist follow-up will cost before booking. Tell the care team if a charge could interrupt treatment. They may be able to discuss a different dispensing arrangement or coordinate necessary testing closer to home.
How to spot an unsafe online seller
A legitimate pharmacy identifies where it dispenses, has a pharmacist you can contact, and asks for a valid prescription. Check its registration through the appropriate pharmacy regulator. Make sure the name and address in the register match the business actually dispensing the tablets. A logo that claims accreditation or a photograph of familiar packaging cannot verify the contents of what a seller sends you.
Avoid sites that offer anastrozole without a prescription or ask you to choose a dose for bodybuilding or hormone suppression. A seller cannot confirm the cause of a laboratory result or monitor a treatment plan simply by shipping tablets. If you have already obtained medicine from an unverified source, keep the packaging and tell a pharmacist or your clinician what you took and when. Seek urgent care if you have serious symptoms.
Frequently asked questions
Do I need a prescription for anastrozole?
Yes. A qualified clinician needs enough information to know why you would take it and whether the plan is suitable. A licensed pharmacy then dispenses the prescription. A website that lists the medicine for sale cannot replace the assessment.
Can an oncologist issue a first prescription at a video visit?
They may be able to when your records establish the diagnosis and treatment plan. If they need to assess ovarian function or investigate a new symptom, another appointment or test may come first. Ask which reports the clinic already has when you book.
What should I send if my treatment was at a different hospital?
Ask for the pathology report with receptor results and the latest treatment summary. Include the names and dates of previous endocrine medicines and any available results that explain why treatment changed. Tell the new clinic whom to contact if it needs the full record.
Can my primary care clinician renew it?
Some primary care clinicians can renew an established prescription under an agreed oncology plan. Confirm who will handle side effects, follow-up tests, and decisions about stopping or switching. A clinician who manages repeats may refer treatment changes back to oncology.
Can I take it if my periods stopped during chemotherapy?
A pause in menstruation after chemotherapy does not always establish menopause. Give the team your treatment dates and menstrual history. They can decide whether ovarian function needs further assessment and whether the plan should include ovarian suppression.
What if I miss an ovarian suppression injection?
Contact the team that manages it. Give the date you were due and the date of your last injection. Ask what to do with your current medicines while the clinic arranges the next step, especially if you have had a return of bleeding.
Can I take it after tamoxifen?
An oncologist may recommend a switch in certain adjuvant plans or consider anastrozole for advanced disease that has progressed after tamoxifen. These situations have different goals. Ask why the switch fits your diagnosis and get a clear stop and start date.
Does anastrozole work in estrogen receptor-negative breast cancer?
The team generally expects endocrine therapy to help when the cancer is hormone receptor-positive. The prescribing information reports that patients with estrogen receptor-negative disease rarely responded in the advanced disease setting it describes. Ask how your receptor report affects the choice of treatment.
Should I get a bone density scan before starting?
Ask your team whether you need a baseline result. A history of osteoporosis, a low-trauma fracture, or another risk factor can affect the assessment. Bring the report if you have had a scan recently so the clinician can decide whether it is still useful.
Can I take anastrozole if I have coronary artery disease?
Tell the oncologist about angina, a heart attack, or treatment for a blocked coronary artery. The decision depends on your expected cancer benefit and your cardiac history. The team can discuss which endocrine options fit and whether it wants another clinician to help manage your heart risk.
Does everybody need regular estradiol tests?
Many patients with established menopause do not need routine estradiol monitoring during therapy. In selected patients whose ovarian function is uncertain or whose treatment depends on suppression, a test can inform a decision. Ask what the clinician would do differently based on the result.
What if joint pain affects work or sleep?
Give the team an example of what the pain prevents you from doing and when you first noticed it. They can assess other causes and discuss ways to manage it or change therapy. Tell them if you have been skipping tablets because of the symptoms.
Can men get a prescription for high estradiol?
A specialist may prescribe an aromatase inhibitor off-label for a specific condition. One estradiol value does not establish that treatment is needed. The clinician considers symptoms, the test method, medicines or hormones you take, and what outcome treatment is meant to improve.
Does anastrozole improve male fertility?
A reproductive urologist may consider it in selected infertile men with low testosterone. Evidence about outcomes such as pregnancy remains limited. Improvements in hormone levels or some semen measurements do not guarantee conception. The specialist can explain what your evaluation shows and which options fit.
Can I use it to prevent breast enlargement while taking testosterone?
Discuss a new breast change with the clinician who prescribes testosterone. They can assess possible causes and examine you if needed. Guidelines do not recommend aromatase inhibitors routinely for gynecomastia, and starting one yourself can make test results harder to interpret.
What should I do if I miss an oncology dose?
Check the instructions that came with your medicine or ask your pharmacist. Avoid doubling up to make up for a missed dose. Contact your care team if missed doses are becoming frequent or if you have run out because of a supply problem.
Can I switch to letrozole or exemestane?
An oncology clinician may discuss a different aromatase inhibitor if side effects are limiting treatment. A change after progression requires a wider review of the regimen. Ask how the switch affects your treatment goal and which checks the team wants after you start.
What if I have a positive pregnancy test?
Contact the team that prescribed it promptly. Give the date of your last dose and the date of the test. The team can advise on the prescription and arrange the appropriate assessment, taking your cancer treatment plan into account.
Can I stop when I feel well or reach the planned end date?
Feeling well does not tell you how much benefit the remaining treatment may provide. If you are approaching the end of a planned course, ask for a review of whether to finish or extend it. If side effects are the reason you want to stop, tell the team what has changed.
Arrange a consultation with the right clinician
For cancer treatment, start with the team that has your pathology and knows what you have already received. Give the clinic your most recent endocrine medication history and say whether you need to start, switch, or refill a prescription. For a male hormone or fertility concern, bring your previous results to a specialist who can assess the symptoms, the reason for testing, and the available treatment options.
- Send the pathology report or the latest treatment letter if the clinic does not have it.
- Bring a list of medicines, supplements, and any recent changes.
- If ovarian suppression is part of your plan, give the date of your last injection.
- Let the team know when your current supply runs out and which pharmacy you use.
If the clinician prescribes anastrozole, leave the consultation with the dose, pharmacy, follow-up date, and contact for side effects or questions about the treatment plan.